Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIN2B | Q13224 | 4/20 | 0.54 |
| ▸ | MEN1 | O00255 | 1/20 | 0.54 |
| ▸ | RAB9A | P51151 | 1/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.54 |
| ▸ | ACHE | P22303 | 3/20 | 0.50 |
| ▸ | BACE1 | P56817 | 3/20 | 0.50 |
| ▸ | BCHE | P06276 | 2/20 | 0.50 |
| ▸ | FYN | P06241 | 1/20 | 0.50 |
| ▸ | FUCA1 | P04066 | 1/20 | 0.47 |
| ▸ | LTA4H | P09960 | 1/20 | 0.47 |
| ▸ | KDM1A | O60341 | 1/20 | 0.46 |
| ▸ | MAOA | P21397 | 1/20 | 0.46 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.45 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14657362 | 0.89 | GRIN2B (0.62) | GRIN2BMEN1RAB9AKMT2AACHE | |
| SCHEMBL5246474 | 0.89 | GRIN2B (0.62) | GRIN2BMEN1RAB9AKMT2AACHE | |
| Hydrochloric Acid SCHEMBL5244788 | 0.87 | MEN1 (0.66) | GRIN2BMEN1RAB9AKMT2AACHE | |
| SCHEMBL30257992 | 0.87 | GRIN2B (0.55) | GRIN2BMEN1RAB9AKMT2AACHE | |
| SCHEMBL23912484 | 0.83 | ACHE (0.48) | MEN1RAB9AKMT2AACHEBACE1 | |
| SCHEMBL663239 | 0.82 | GRIN2B (0.74) | GRIN2BMEN1RAB9AKMT2AACHE | |
| Methyl Alcohol SCHEMBL27513196 | 0.81 | GRIN2B (0.67) | GRIN2BMEN1RAB9AKMT2AACHE | |
| Hydrochloric Acid SCHEMBL2550113 | 0.81 | MEN1 (0.78) | GRIN2BMEN1RAB9AKMT2AACHE | |
| SCHEMBL24511684 | 0.80 | FUCA1 (0.54) | GRIN2BMEN1RAB9AKMT2AACHE | |
| SCHEMBL24511683 | 0.80 | FUCA1 (0.54) | GRIN2BMEN1RAB9AKMT2AACHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-102186812-A | Methods for preparing fluoroalkyl arylsulfinyl compounds and fluorinated compounds thereto | UBE INDUSTRIES | 2011-09-14 | — | — | CN | disclosed |
| US-20110190511-A1 | Methods For Preparing Fluoroalkyl Arylsulfinyl Compounds And Fluorinated Compounds Thereto | IM&T RESEARCH, INC. (US) | 2011-08-04 | — | — | US | disclosed |
| EP-2323974-A1 | METHODS FOR PREPARING FLUOROALKYL ARYLSULFINYL COMPOUNDS AND FLUORINATED COMPOUNDS THERETO | Ube Industries, Ltd. (JP) | 2011-05-25 | — | — | EP | disclosed |
| US-20100152463-A1 | Methods for Preparing Fluoroalkyl Arylsulfinyl Compounds and Fluorinated Compounds Thereto | IM&T RESEARCH, INC. (US) | 2010-06-17 | — | — | US | disclosed |
| WO-2010022001-A1 | METHODS FOR PREPARING FLUOROALKYL ARYLSULFINYL COMPOUNDS AND FLUORINATED COMPOUNDS THERETO | IM&T RESEARCH, INC. (US) | 2010-02-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100152463-A1 | Methods for Preparing Fluoroalkyl Arylsulfinyl Compounds and Fluorinated Compounds Thereto | PFAS, AGPS, FDPS | GRIN2B 3262/4885MEN1 2099/4885RAB9A 923/4885 |
| US-20110190511-A1 | Methods For Preparing Fluoroalkyl Arylsulfinyl Compounds And Fluorinated Compounds Thereto | PFAS, AGPS, FDPS | GRIN2B 2948/4885MEN1 1047/4885RAB9A 991/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.